In July 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended not to reimburse dupilumab.[1] Continue reading “Dupilumab (Dupixent®): CADTH Publishes Negative Recommendation for Reimbursement in Canada”
Between March 2017 and January 2018 Dupilumab was approved in four major global regions: the US[1], the EU[2], Canada[3], and Japan.[4] Continue reading “Dupilumab (Dupixent®): NICE Publishes Positive Final Appraisal Determination”
Dupilumab, first approved in early 2017 in the US[1], and subsequently approved in the EU (September 2017) [2] and Canada (December 2017)[3], has now also been approved in Japan.[4] Continue reading “Dupilumab (Dupixent®): Now also approved in Japan”
Following on from the first global approval[1] of dupilumab in the US and the subsequent follow-up approval in the EU[2], dupilumab (Dupixant®), developed by Sanofi and Regeneron was approved by Health Canada in early December 2017 Continue reading “Dupilumab (Dupixant®): Now available in Canada”
The recent first global approval of dupilumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema”